Trial Profile
Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms GAZAI
- 10 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2021 Planned End Date changed from 1 Sep 2023 to 1 May 2024.
- 25 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Nov 2021.